Core Insights - Elutia Inc. has developed a validated method for measuring antibiotic release from a biologic envelope, which accelerates product development and testing [1][2] - The new method provides reliable data in 30 hours, significantly faster than the traditional 14-day in vivo protocols, enhancing efficiency in drug release testing [2][3] - EluPro, the first FDA-cleared antibiotic-eluting bioenvelope, was launched in January 2025 and is designed for use with cardiac implantable electronic devices and neurostimulators [3] Company Overview - Elutia focuses on drug-eluting biomatrix products to improve compatibility between medical devices and patients, aiming to humanize medicine for those needing implantable technologies [5] - The company emphasizes the importance of drug elution performance for manufacturing consistency and regulatory evaluation, as recognized by the FDA [2][3] - Elutia's innovative approach supports the product lifecycle of EluPro and future drug-eluting biologic matrices, showcasing its leadership in the field [3]
Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method